Management of infection in neutropenic patients

Current Opinion in Infectious Diseases

Volumn 10, Issue 4, 1997, Pages 255-261

  Philpott Howard, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR; MEROPENEM;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; INFECTION; LABORATORY DIAGNOSIS; MYCOSIS; NEUTROPENIA; REVIEW;

EID: 0030857668     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199708000-00002     Document Type: Review

References (47)

1. Bow EJ, Loewen R, Vaughan D: Reduced requirement for antibiotic therapy targeting Gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995, 20:907-912.
2. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F: Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996, 15:291-296. A useful analysis of trends in episodes of bacteraemia in neutropenic patients over 7 years. The incidence of bacteraemia increased significantly from 20 to 50 episodes per 1000 admissions, with an increase in Gram-positive bacteraemia and a stable incidence of Gram-negative bacteraemia. Intravascular catheters and oral mucositis were the most important sources of infection, when identified.
3. Oethinger M, Conrad S, Kaifel K, Comettta A, Bille J, Klotz G, Glauser MP, Marre R, the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, Kern WV: Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centres. Antimicrob Agents Chemother 1996, 40:387-392. Pulse-field gel electrophoresis of quinolone-resistant E. coli isolated from blood cultures from cancer patients showed that strains were found to be distinguishable, and therefore the monoclonal spread of these organisms is unlikely. A third of strains, however, were not typable.
4. Carratala J, Fernandez-Sevilla A, Tubua F, Dominguez MA, Gudiol F: Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996, 40:503-505.
5. Bruun B, Westh H, Stenderup J: Fungemia: an increasing problem in a Danish university hospital 1989 to 1994. Clin Microbial Infect 1995, 1:124-126.
6. Pfaller M: Epidemiology and control of fungal infections. Clin Infect Dis 1994, 19(Suppl 1):S8-S13.
7. Viscoli C, Girmenia C, Marinus A, Martino P, Meunier F: A surveillance study of fungemia in cancer patients in Europe. Abstract presented at Trends in Invasive Fungal Infections. Brussels, Belgium, September 1995,.
8. GirmeniaC, Martino P, De Bernardis F, Gentile G, Boccanera M, Monaco M, Antonucci G, Cassone A: Rising incidence of Candida parapsilosis fungemia in hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996, 23:506-514. C. parapsilosis caused 35 of 138 fungaemic episodes in an Italian cancer centre; the central venous catheter was the most common source of infection and catheter removal was required in many cases to effect a cure. C. parapsilosis was the most common species causing infection acquired at home during outpatient care. Certain strains, particularly those from patients with severe invasive disease, were shown to be more virulent than others in a mouse model. Approximately half of the strains were tolerant of fluconazole and itraconazole although full resistance was rare.
9. Cassone A, De Bernardis F, Pontieri E: Biotype diversity of Candida parapsilosis and its relationship to the clinical source of experimental pathogenicity. J Infect Dis 1995, 171:967-975.
10. Holt CD, Winston DJ, Kubak B, Imagawa DK, Martin P, Goldstein L, Olthoff K, Millis JM, Shaked A, Shackleton CR, Busuttil RW: Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997, 24:216-221. A review of 1347 liver transplant patients at UCLA (Los Angeles) showed that in this high-risk area for coccidioides infection eight patients (0.59%) developed disease. Any questioning of immunocompromised patients, including those due to receive chemotherapy or bone marrow transplantation, must include past geographical locations.
11. Duong TA: Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996, 23:125-130.
12. Shelhamer JH, Gill VJ, Quinn TC, Crawford SW, Kovacs JA, Ognibene FP: The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 124:585-599.
13. Jolis R, Castella J, Puzo C, Coll P, Abeledo C: Diagnostic value of protected BAL in diagnosing pulmonary infections in immunocompromised patients. Chest 109:601-607. This paper studied various methods for obtaining the best clinical specimen at bronchoscopy. Protected specimen brush was least sensitive in detecting pathogens; bronchoalveolar lavage had more contamination from upper respiratory flora; protected bronchoalveolar lavage was as good as bronchoalveolar lavage but with fewer false-positives; it yielded most pathogens and there was less contamination.
14. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996, 23:608-615. This study analysed 1223 cases of invasive aspergillosis published in the world literature where more than three cases were reported. Crude mortality rates were 86, 66 and 99% for pulmonary, sinus and cerebral disease, respectively. If specific treatment could be given for more than 14 days, the response rate was 54% in leukaemic patients and only 33% in bone marrow transplant recipients. The mortality of cerebral aspergillosis was 99%. There was some evidence that mortality was lower in patients who were treated with itraconazole or lipid preparations of amphotericin B.
15. Horvath JA, Dummer S: The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100:171-178.
16. Stynen D, Sarfati J, Goris A, Prévost MC, Lesourd M, Kamphuis H, Darras V, Latgé JP:Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 1992, 60:2237-2245.
17. Swanink CMA, Meis JFGM, Tijs AJMM, Donnelly JP, Verweij PE: Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997, 35:257-260.
18. Bart-Delabesse E, Marmorat-Khuong A, Costa JM, Dubreuil-Lemaire ML, Bretagne S: Detection of Aspergillus DNA in bronchoalveolar lavage fluid of AIDS patients by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 1996, 15:24-25.
19. Takaki K, Shimono N, Ishimaru T, Okada K, Sawae Y, Niho Y: Detection of Candida antigen and antibody in serum from patients with invasive candidiasis. Int J Infect Dis 1996, 1:78-82.
20. Desselle BC, Bozeman PM, Patrick CC: Diagnostic utility of thoracentesis for neutropenic children with cancer. Clin Infect Dis 1995, 21:887-890.
21. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Falvero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J et al.: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Infection Program. Antimicrob Agents Chemother 1996, 40:1108-1115. Meropenem was compared with ceftazidime-amikacin in 1034 patients with febrile neutropenia. There was no difference between the two groups with regard to any of the outcome measures, with successful treatment in 57 and 52% of patients receiving meropenem and ceftazidime-amikacin, respectively. Mortality was very low (eight and 13 deaths in each group, respectively). The study drugs were all very well tolerated, with few adverse reactions. Meropenem may be suitable for the management of febrile neutropenic patients, especially if other agents are unsuitable.
22. Rossi C, Klastersky J: Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death. Support Care Cancer 1996, 4:207-212.
23. Cometta A, Viscoli C, Castagnola E, Massimo L, Giacchino R, Gibson B, Balbo L, Engelhard D, Shapiro M, Amsallem D et al.: Empirical treatment of fever in neutropenic children: the role of the carbapenems. Pediatr Infect Dis J 1996, 15:744-748.
24. Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, Ghaddar HM, Karl CL, Bodey GP: A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic patients. Cancer 1996, 77:1386-1394.
25. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE: Early identification of neutropenic patients at risk of Gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996, 32A:1332-1339. A randomized study showed that vancomycin need not be included in the primary treatment regimen even if there was clinically evident skin and soft tissue infection. Although vancomycin eradicated Gram-positive bacteria better than ceftazidime or piperacillin-gentamicin, it did not improve the clinical outcome and there was some toxicity.
26. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D: Clinical experience with single agent and combination regimens in the management of infections in the febrile neutropenic patient. Am J Med 1996, 100(Suppl):83S-89S.
27. De Pauw BE, Dompeling EC: Antibiotic strategy after the empiric phase in patients treated for a haematological malignancy. Ann Hematol 1996, 72:273-279. This study analysed 1951 febrile neutropenic episodes and showed that unnecessary additions or changes to therapy were often made. Twenty-five per cent of changes were associated with objective reasons at night compared with 93% during the day. Empirical change was, however, indicated when new specific localizing signs were noted, and in such cases modification was often reasonable.
28. Anaissie EJ, Vartivarian SE, Abisaid D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II et al.: Fluconazole versus amphotericin B in the treatment of invasive candidiasis: a matched cohort study. Am J Med 1996, 101:170-176
29. Cole GT, Halawa AA, Anaissie EJ: The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996, 22(Suppl 2):S73-S88.
30. Blumberg EA, Reboli AC: Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996, 22:462-466.
31. Powderly WG, Kobayashi GS, Herzig GP, Medoff G: Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988, 84:826-832.
32. Guiot HFL, Fibbe WE, van 't Wout JW: Prevention of invasive candidiasis by fluconazole in patients with malignant hematological disorders and a high grade of candida colonisation [Abstract LM33]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans; 1996.
33. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, Geller R, Wingard JR: Isolation and characterization of fluconazole-and amphotericin B-resistant yeasts from blood of two patients with leukemia. Antimicrob Agents Chemother 1997, 41:196-199.
34. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff AE, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL for the Subcommittee on Antifungal Susceptibility Testing of the National Committee of Clinical Laboratory Standards: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and candida infections. Clin Infect Dis 1997, 24:235-247.
35. Mills W, Chopra R, Linch DC, Goldstone AH: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994, 86:754-760.
36. Ellis M, Spence D, Meunier F, De Pauw B, Bogaerts M, Van Der Cam B, Doyen C, Marinus A, Collette L, Sylvester R: Randomized multicentre trial of 1 mg/kg versus 4 mg/kg liposomal amphotericin B (Ambisome) in the treatment of invasive aspergillosis. EORTC Protocol 19923 [Abstract LM39]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans; 1996.
37. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW: Itraconazole oral solution vs fluconazole suspension for antifungal prophylaxis in neutropenic patients [Abstract LM34]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans; 1996.
38. Ayestaran A, Lopez RM, Montoro JB, Estibalez A, Pou L, Julia A, Lopez A, Pascual B: Pharmacokinetics of conventional formulation amphotericin B versus fat emulsion in a group of patients with neutropenia. Antimicrob Agents Chemother 1996, 40:609-612.
39. Pascual B, Ayestaran A, Montoro JB, Oliveras J, Estíbalez A, Julia A, Lopez A: Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995, 29:1197-1201.
40. Martin MV, Yates J, Hitchcock CA: Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997, 41:13-16.
41. Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996, 40:279-291.
42. Leong KW, Crowley B, White ?, Crotty GM, O'Briain DS, Keane C, McCann SR: Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant 1997, 19:513-515.
43. Bouza E, Muñoz P, Vega L, Rodríguez-Créixems M, Berenguer J, Escudero A: Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996, 23:192-193.
44. Gonzalez CE, Couriel DR, Walsh TJ: Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997, 24:192-196.
45. Katoh M, Takada M, Nakayama M, Umeda M: Pulmonary toxicity during granulocyte colony stimulating factor administration and neutrophils. Chest 1996, 110:576-577.
46. Wingard JR, Elfenbein GJ: Host immunologic augmentation for the control of infection. Infect Dis Clin North Am 1996, 10:345-364.
47. Walsh TJ, Hiemenz JW, Anaissie E: Recent progress and current problems in treatment of fungal infections in neutropenic patients. Infect Dis Clin North Am 1996, 10:365-400.